Renaissance Capital logo


Renaissance Capital's November IPO Market Update


Eleven US IPOs raised a combined $708 million in November, well below the month's historical 10-year average (16 IPOs, $4.2B). Deal flow was led by three sizable issuers, and remaining activity came from smaller companies, all of which raised $33 million or less. The month's IPOs averaged a weak -22% return from offer, and only two deals finished above issue, both of which more

US IPO Weekly Recap: IPO market sees a little activity in the short holiday week


One small IPO and one SPAC priced this past week as markets slowed around the Thanksgiving holiday. Skincare company Elevai Labs (ELAB) priced at the low end to raise $6 million at a $69 million market cap. Small and highly unprofitable, the company offers “physician-dispensed” skincare products, meaning they are sold exclusively in physician more

Skincare company Elevai Labs prices IPO at $4, the low end of the range


Elevai Labs, which makes physician-dispensed skincare products, raised $6 million by offering 1.5 million shares at $4, the low end of the range of $4 to $6. Elevai Labs is a physician-dispensed skincare company, which refers to a sales channel where cosmetics products are exclusively sold in physician clinics or medically directed businesses by licensed medical professionals more

US IPO Weekly Recap: Holdover Adlai Nortye leads 4 IPO week as more small deals enter the pipeline


The third quarter wrapped up with four IPOs and eight pipeline additions. Oncology biotech Adlai Nortye (ANL) raised $58 million at an $849 million market cap. The company originally planned to raise $72 million in August but never priced; it removed and then set new terms earlier this month. Operating through subsidiaries in the US and China, more